pharmaphorum

JANUARY 5, 2022

Other drugmakers have been looking at Met as a target in cancer, including Novartis, Merck KgAA and Hutchmed, which have all bagged regulatory approvals for oral therapies that target NSCLC harbouring a specific mutation in Met known as exon 14 skipping which affects about 3% to 4% of NSCLC patients.

Antibody 110

Antibody Drugs Protein Gene 110

The Pharma Data

MAY 5, 2021

Roger Perlmutter, former Merck R&D head, becomes CEO of super-microscopy startup ( STAT ) ( Endpoints ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). Merck KGaA raises forecast for full year 2021 ( Pharmaletter ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

Drug Discovery World

NOVEMBER 13, 2023

Immunocytokines Following chairperson’s remarks from Stefan Zielonka, PhD, Global Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA; Professor of Biomolecular Immunotherapy, Technical University of Darmstadt, there will be a keynote presentation from Roberto De Luca, PhD, Head, Therapeutic Antibodies, Philochem.

Protein 59

Protein Antibody Engineer Scientist 59